Evaluating Modes of Influenza Transmission (EMIT-2) using Innovative Technologies and Designs in Controlled Environments
Project Number1U19AI162130-01
Contact PI/Project LeaderMILTON, DONALD KIRBY
Awardee OrganizationUNIV OF MARYLAND, COLLEGE PARK
Description
Abstract Text
Project Summary/Abstract – Overall Component
We propose multidisciplinary studies to comprehensively evaluate the roles of contact, fomite, sprayborne, and
aerosol transmission and how they interact with ventilation to facilitate human-to-human influenza transmission
using a suite of innovative technologies for improved sampling, fractionation, culture, and characterization of
influenza virus aerosols. These studies leverage our highly diverse team of experts in bioengineering, aerosol
science, human challenge and clinical trials, influenza virology and immunology, infectious diseases
epidemiology, aerobiology, and computational fluid dynamics. The proposal is organized around two research
projects and three cores. In Research Project 1, “Evaluating Modes of Influenza Transmission using a
Randomized Controlled Trial (EMIT-2-RCT)” we will study the impact of two interventions a) ventilation and air
sanitation and b) hand hygiene and face shields on transmission of circulating seasonal influenza from
naturally infected cases to serologically susceptible volunteers. We will use the RCT to test hypotheses that
aerosol transmission is the dominant mode, is associated with greater frequency of fever and systemic
symptoms in secondary cases, and that in the absence of hemagglutination inhibiting antibodies, antibodies
against other targets will strongly correlate with protection from infection and disease. In Research Project 2,
“Developing and Applying Analytical Models of Influenza Transmission” we will use computational fluid
dynamics and novel new aerosol measurements to a) design interventions and sampling strategies for the
RCT enabling us to distinguish short- and long-range aerosol transmission from sprayborne transmission, b)
define the Wells-Riley aerosol quantum of infection in terms of measurable quantities and assess risk at the
recipient breathing zone level in both well-mixed and non-well-mixed indoor air conditions, and c) extend our
models to household and animal studies and create practical analytical tools for public health scientists to
collect data and assess risk in the field. The Research Projects will be enabled by an Advanced Bioaerosol
Technology Core (ABTC) that will develop new viral aerosol sampling and culture systems and methods for
both ambient and exhaled breath sampling that will validate the RCT design and provide critical inputs to the
analytical models. A Clinical and Biostatistics Core (CBC) will provide the clinical infrastructure to perform the
complex quarantine studies. The Administrative Core will manage these tightly integrated components to mold
transdisciplinary insights into the dynamics and drivers of influenza transmission between humans.
Public Health Relevance Statement
Project Narrative – Overall Component
Influenza is a major problem worldwide, and despite decades of research, many questions remain about the
factors that affect transmission, particularly how various routes of infection contribute to transmission and
disease severity. This U19 Project addresses a critical need to improve the understanding of influenza
transmission in humans. To this end, our consortium of world-renowned virologists, immunologists,
epidemiologists, aerosol scientists, computational fluid dynamic modelers, aerobiologists, and engineers is
developing and applying state-of-the-art methods to examine transmission including the use of an experimental
human transmission study and analytical models of bioaerosols.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
790934285
UEI
NPU8ULVAAS23
Project Start Date
01-September-2021
Project End Date
31-May-2026
Budget Start Date
01-September-2021
Budget End Date
31-May-2022
Project Funding Information for 2021
Total Funding
$3,024,086
Direct Costs
$2,552,332
Indirect Costs
$471,754
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$3,024,086
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U19AI162130-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U19AI162130-01
Patents
No Patents information available for 1U19AI162130-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U19AI162130-01
Clinical Studies
No Clinical Studies information available for 1U19AI162130-01
News and More
Related News Releases
No news release information available for 1U19AI162130-01
History
No Historical information available for 1U19AI162130-01
Similar Projects
No Similar Projects information available for 1U19AI162130-01